Streetbeat News

Partnerships

AGRX

Agile Therapeutics, Inc. (NASDAQ:AGRX) has announced partnerships with FPA Women's Health and vitaCare Prescription Services to expand access to its low-dose weekly birth control patch, Twirla. The partnerships will help Agile reach its target net revenue of $25-$30 million for the year. Telehealth platforms like Nurx, which Agile has also partnered with, provide birth control prescriptions and other basic healthcare services to patients nationwide, filling gaps in America's contraception landscape.

Portfolio Pulse from Happy Mohamed

July 18, 2023 | 1:04 pm

FTRE

IXHL

Incannex Healthcare Limited (NASDAQ:IXHL) has engaged Fortrea (NASDAQ:FTRE) to manage the IND opening phase 2/3 clinical trial of its drug IHL-42X for the treatment of obstructive sleep apnea. The trial will assess the safety and efficacy of IHL-42X over a 52-week treatment period. The initial phase 2 trial demonstrated a significant reduction in the Apopnea Hypopnea Index score and improved sleep quality.

Portfolio Pulse from Vuk Zdinjak

July 18, 2023 | 1:03 pm

BWA

ON

onsemi (NASDAQ:ON) and BorgWarner Inc. (NYSE:BWA) have expanded their strategic collaboration for silicon carbide (SiC), making the total agreement worth over $1 billion in lifetime value. BorgWarner plans to integrate onsemi's EliteSiC 1200 V and 750 V power devices into its VIPER power modules for traction inverter solutions to increase the performance of electric vehicles.

Portfolio Pulse from Happy Mohamed

July 18, 2023 | 1:03 pm

MDB

MSFT

MongoDB has expanded its global collaboration with Microsoft. Developers who access the Azure portal will now be able to discover and use MongoDB Atlas. This strategic partnership is aimed at accelerating workload migrations to MongoDB Atlas on Microsoft Azure.

Portfolio Pulse from Benzinga Newsdesk

July 18, 2023 | 1:02 pm

PLTR

Palantir Technologies Inc (NYSE:PLTR) shares continue to rise after hitting new 52-week highs. The surge is driven by a new partnership with SpecterOps, strong demand for its AI platform, and better-than-expected quarterly results. The company has scheduled its second-quarter financial results for Aug. 7.

Portfolio Pulse from Adam Eckert

July 18, 2023 | 1:01 pm

HPQ

THD

HP is planning to relocate part of its notebook production to Thailand, with Quanta Computer serving as its primary supplier, according to DigiTimes.

Portfolio Pulse from Charles Gross

July 18, 2023 | 12:53 pm

XELA

Exela Technologies, Inc. (NASDAQ: XELA, XELAP) announced that it has signed several additional US counties for its Digital Mailroom solution, contributing to its ITPS segment which generated $765 million of revenue in 2022. The company is working with various counties to provide a secure, end-to-end solution for digital transformation and compliance requirements.

Portfolio Pulse from Happy Mohamed

July 18, 2023 | 12:47 pm

MSFT

TDOC

Teladoc Health Inc (TDOC) shares are trading higher after the company announced an expanded collaboration with Microsoft Corp (MSFT) to address the healthcare workforce crisis. The collaboration will integrate Microsoft Azure OpenAI Service, Azure Cognitive Services, and the Nuance Dragon Ambient eXperience into the Teladoc Health Solo platform. The solutions will automate the clinical documentation process during virtual exams and improve the quality of shared medical information.

Portfolio Pulse from Adam Eckert

July 18, 2023 | 12:41 pm

BPTS

MICS

PLTR

Biophytis partners with SEQENS to produce Sarconeos (BIO101) active compound, causing a surge in BPTS stock by 87%. Singing Machine expands retail presence with Walmart, leading to a 50% increase in MICS stock. Palantir's FedStart offering now includes BloodHound Enterprise from SpecterOps, resulting in a 4% rise in PLTR stock.

Portfolio Pulse from ryanfaloona@benzinga.com

July 18, 2023 | 12:40 pm

GNPX

Genprex, Inc. (NASDAQ: GNPX) has signed an exclusive license agreement with the University of Pittsburgh for a gene therapy for both Type 1 and Type 2 diabetes. The therapy uses the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter. The newly licensed technology is based on the same general gene therapy approach under Genprex's original license. Preclinical data shows significant decreases in insulin requirements, increases in c-peptide levels, and improvements in glucose tolerance.

Portfolio Pulse from Happy Mohamed

July 18, 2023 | 12:39 pm